Business
Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada
BOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented
About this update from Sonoma Pharmaceuticals, Inc.
[{"type":"text","content":"BOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it has entered into an amendment to its distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in Canada.As previously announced, on August 19, 2024, Sonoma entered into a distribution agreement with a global healthcare distributor for the marketing and distribution of its wound care products in the United States, to be sold through hospital systems and other healthcare channels. The new amendment allows the same distributor to also distribute these products in Canada, and adds over-the-counter wound care products for sale in both countries.\"This expanded partnership with a global healthcare distributor will enable us to bring our wound care products and the regenerative power of Microcyn technology to Canada,\" said Amy Trombly, CEO of Sonoma. \"Our distributor's expertise and distribution network will allow new patients in Canada the opportunity to benefit from improved management of both acute and chronic wounds, reduction in pain, itch and scarring, and the peace of mind that results from Sonoma's safe and effective technology. We are also pleased that our distributor plans to sell over-the-counter products as well, allowing consumers to benefit from greater accessibility of our wound care products.\"Further information about the amendment can be found in the Current Report on Form 8-K filed by Sonoma with the U.S. Securities and Exchange Commission on October 22, 2024.About Sonoma Pharmaceuticals, Inc.Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely m...